Published in Cancer Weekly, February 8th, 2005
VISTA is a multicenter, international phase 3 clinical trial of Velcade in combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates. This large, international randomized study will assess efficacy, overall safety and tolerability of the combination versus melphalan and prednisone alone.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.